A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report

We report our experience in the management of a relapsed ovarian cancer patient with somatic RAD51C mutation, treated with olaparib monotherapy. The patient was diagnosed with stage 4 high-grade serous ovarian carcinoma and was treated with neoadjuvant chemotherapy, cytoreductive surgery, and postop...

Descripción completa

Detalles Bibliográficos
Autores principales: Ngu, Siew-Fei, Ngan, Hextan Y. S., Chan, Karen K. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511802/
https://www.ncbi.nlm.nih.gov/pubmed/36176748
http://dx.doi.org/10.20517/cdr.2022.12
_version_ 1784797717903441920
author Ngu, Siew-Fei
Ngan, Hextan Y. S.
Chan, Karen K. L.
author_facet Ngu, Siew-Fei
Ngan, Hextan Y. S.
Chan, Karen K. L.
author_sort Ngu, Siew-Fei
collection PubMed
description We report our experience in the management of a relapsed ovarian cancer patient with somatic RAD51C mutation, treated with olaparib monotherapy. The patient was diagnosed with stage 4 high-grade serous ovarian carcinoma and was treated with neoadjuvant chemotherapy, cytoreductive surgery, and postoperative chemotherapy. After a second cancer recurrence, she underwent FoundationOne CDx testing following disease progression on multiple lines of chemotherapy. Based on the FoundationOne CDx results, olaparib monotherapy was started. After 13 months of therapy, all lesions responded to the treatment, and she achieved complete response as demonstrated by normalization of the levels of CA125 and positron emission tomography-computed tomography (PET-CT). We plan to continue olaparib monotherapy until disease progression.
format Online
Article
Text
id pubmed-9511802
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher OAE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-95118022022-09-28 A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report Ngu, Siew-Fei Ngan, Hextan Y. S. Chan, Karen K. L. Cancer Drug Resist Case Report We report our experience in the management of a relapsed ovarian cancer patient with somatic RAD51C mutation, treated with olaparib monotherapy. The patient was diagnosed with stage 4 high-grade serous ovarian carcinoma and was treated with neoadjuvant chemotherapy, cytoreductive surgery, and postoperative chemotherapy. After a second cancer recurrence, she underwent FoundationOne CDx testing following disease progression on multiple lines of chemotherapy. Based on the FoundationOne CDx results, olaparib monotherapy was started. After 13 months of therapy, all lesions responded to the treatment, and she achieved complete response as demonstrated by normalization of the levels of CA125 and positron emission tomography-computed tomography (PET-CT). We plan to continue olaparib monotherapy until disease progression. OAE Publishing Inc. 2022-06-22 /pmc/articles/PMC9511802/ /pubmed/36176748 http://dx.doi.org/10.20517/cdr.2022.12 Text en © The Author(s) 2022. https://creativecommons.org/licenses/by/4.0/© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Case Report
Ngu, Siew-Fei
Ngan, Hextan Y. S.
Chan, Karen K. L.
A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report
title A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report
title_full A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report
title_fullStr A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report
title_full_unstemmed A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report
title_short A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report
title_sort patient with relapsed high-grade serous ovarian carcinoma with somatic rad51c mutations treated with parpi monotherapy: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511802/
https://www.ncbi.nlm.nih.gov/pubmed/36176748
http://dx.doi.org/10.20517/cdr.2022.12
work_keys_str_mv AT ngusiewfei apatientwithrelapsedhighgradeserousovariancarcinomawithsomaticrad51cmutationstreatedwithparpimonotherapyacasereport
AT nganhextanys apatientwithrelapsedhighgradeserousovariancarcinomawithsomaticrad51cmutationstreatedwithparpimonotherapyacasereport
AT chankarenkl apatientwithrelapsedhighgradeserousovariancarcinomawithsomaticrad51cmutationstreatedwithparpimonotherapyacasereport
AT ngusiewfei patientwithrelapsedhighgradeserousovariancarcinomawithsomaticrad51cmutationstreatedwithparpimonotherapyacasereport
AT nganhextanys patientwithrelapsedhighgradeserousovariancarcinomawithsomaticrad51cmutationstreatedwithparpimonotherapyacasereport
AT chankarenkl patientwithrelapsedhighgradeserousovariancarcinomawithsomaticrad51cmutationstreatedwithparpimonotherapyacasereport

Ejemplares similares